Skip to content
OpenCapital
Get started

Innoviva, Inc. INVA Research And Development Support — Future Potential Milestone Payment

Similar metrics at other companies

Tarsus Pharmaceuticals, Inc. logo
TARSDevelopment and Regulatory Milestone — Milestone payments to be achieved
$67.5M0.0%
Nuvation Bio logo
NUVBResearch And Development Service Revenue — Milestone Received
$3.8M—
Dianthus Therapeutics logo
DNTHFirst Development Program — Potential Milestone Payments Due
$4.1M+2.5%
Ionis Pharmaceuticals logo
IONSMaximum Amount Of Payments Receivable For Additional Milestones
$625M—
Tarsus Pharmaceuticals, Inc. logo
TARSDevelopment and Regulatory Milestone — Maximum milestone payments
$20M0.0%
Zymeworks logo
ZYMEResearch Milestone — Research and development collaborations (note 11)
$8.75M—

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B—
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K—
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%—
Debt / equity0.2×—
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept inva:FuturePotentialMilestonePayment.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s research and development support — future potential milestone payment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s research and development support — future potential milestone payment?
Innoviva, Inc. (INVA) reported research and development support — future potential milestone payment of $91M in Q1 2026.
How has Innoviva, Inc.'s research and development support — future potential milestone payment changed year-over-year?
Innoviva, Inc.'s research and development support — future potential milestone payment decreased by 0.0% year-over-year, from $91M to $91M.
What is the long-term trend for Innoviva, Inc.'s research and development support — future potential milestone payment?
Over 2 years (2023 to 2025), Innoviva, Inc.'s research and development support — future potential milestone payment has grown at a 0.0% compound annual growth rate (CAGR), from $364M to $364M.
What does research and development support — future potential milestone payment mean?
This metric represents the aggregate value of contingent payments expected upon the successful achievement of specific clinical, regulatory, or commercial development milestones. It serves as a forward-looking indicator of potential future cash inflows tied to the advancement of the company's R&D pipeline. Investors use this to assess the upside potential and risk profile associated with the company's collaborative research agreements.